Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00054595.xml
Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2025; 83(07): s00451809881
DOI: 10.1055/s-0045-1809881
DOI: 10.1055/s-0045-1809881
Review Article
Practical issues in the management of sleep, anxiety, and mood disorders in primary headaches
Abstract
There are many conditions associated with primary headaches, including mood (depression), anxiety, and sleep disorders, which are highly prevalent in the general population and in tertiary headache centers. We call this set of symptoms migraine, anxiety, mood, and sleep (MAMS). The presence of one or more of these symptoms can alter the clinical course and represent a practical challenge. In the present study, we aimed to describe a practical approach to treat these symptoms frequently associated with headaches. Diagnostic aspects and secondary causes were addressed as well as the shared mechanisms and cause and effect relationship. Finally, we commented on the therapeutic approach used to treat these symptoms.
Keywords
Headache Disorders - Migraine Disorders - Sleep Wake Disorders - Anxiety Disorders - Mood DisordersAuthors' Contributions
Conceptualization: PEMSS, MPFF; Data curation: PEMSS; Formal analysis: PEMSS, MPFF; Investigation: PEMSS; Methodology: PEMSS, MPFF; Project administration: MPFF; Supervision: MPFF; Writing – original draft: PEMSS; Writing – review & editing: PEMSS, MPFF.
Editor-in-Chief: Hélio A. G. Teive.https://orcid.org/0000-0003-2305-1073
Associate Editor: Pedro André Kowacs.https://orcid.org/0000-0001-7770-7475
Publication History
Received: 20 October 2024
Accepted: 17 April 2025
Article published online:
02 July 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
Bibliographical Record
Patrick Emanuell Mesquita Sousa-Santos, Mario Fernando Prieto Peres. Practical issues in the management of sleep, anxiety, and mood disorders in primary headaches. Arq Neuropsiquiatr 2025; 83: s00451809881.
DOI: 10.1055/s-0045-1809881
Patrick Emanuell Mesquita Sousa-Santos, Mario Fernando Prieto Peres. Practical issues in the management of sleep, anxiety, and mood disorders in primary headaches. Arq Neuropsiquiatr 2025; 83: s00451809881.
DOI: 10.1055/s-0045-1809881
-
References
- 1 GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396 (10258): 1204-1222 10.1016/S0140-6736(20)30925-9
- 2 Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA, Zukerman E. A nationwide population-based study of migraine in Brazil. Cephalalgia 2009; 29 (06) 642-649 [Internet]
- 3 Caponnetto V, Deodato M, Robotti M, Koutsokera M, Pozzilli V, Galati C. et al; European Headache Federation School of Advanced Studies (EHF-SAS). Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain 2021; 22 (01) 71
- 4 Merikangas KR, Stevens DE. Comorbidity of migraine and psychiatric disorders. Neurol Clin 1997; 15 (01) 115-123
- 5 Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L. et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache 2011; 51 (07) 1058-1077
- 6 Peres MFP, Valença MM, Silva-Neto RP. Management of psychiatric comorbidities in migraine. Vol. 9. Headache Med 2018; 9 (02) 61-67
- 7 Hesdorffer DC. Comorbidity between neurological illness and psychiatric disorders. CNS Spectr 2016; 21 (03) 230-238
- 8 Lipton RB, Fanning KM, Buse DC, Martin VT, Reed ML, Adams AM, Goadsby PJ. Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache 2018; 58 (07) 933-947
- 9 Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T. et al; European Headache Federation School of Advanced Studies (EHF-SAS). Migraine and sleep disorders: a systematic review. J Headache Pain 2020; 21 (01) 126
- 10 Kim J, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK. Insomnia in tension-type headache: a population-based study. J Headache Pain 2017; 18 (01) 95
- 11 Vgontzas A, Pavlović JM. Sleep Disorders and Migraine: Review of Literature and Potential Pathophysiology Mechanisms. Headache 2018; 58 (07) 1030-1039
- 12 Louter MA, Wilbrink LA, Haan J, van Zwet EW, van Oosterhout WPJ, Zitman FG. et al. Cluster headache and depression. Neurology 2016; 87 (18) 1899-1906
- 13 Lu G, Xiao S, He J, Xie W, Ge W, Meng F. et al. Prevalence of depression and its correlation with anxiety, headache and sleep disorders among medical staff in the Hainan Province of China. Front Public Health 2023; 11: 1122626
- 14 Waszczuk MA, Zimmerman M, Ruggero C, Li K, MacNamara A, Weinberg A. et al. What do clinicians treat: Diagnoses or symptoms? The incremental validity of a symptom-based, dimensional characterization of emotional disorders in predicting medication prescription patterns. Compr Psychiatry 2017; 79: 80-88
- 15 Do TP, Remmers A, Schytz HW, Schankin C, Nelson SE, Obermann M. et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology 2019; 92 (03) 134-144
- 16 Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American academy of sleep medicine clinical practice guideline. J Clin Sleep Med 2017; 13 (03) 479-504
- 17 Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain 2017; 18 (01) 37
- 18 Nogueira EAG, Oliveira FR, Carvalho VM, Telarolli C, Fragoso YD. Catastrophization is related to the patient and not to the severity of migraine. Arq Neuropsiquiatr 2021; 79 (08) 682-685
- 19 Peres MFP, Mercante JPP, Guendler VZ, Corchs F, Bernik MA, Zukerman E, Silberstein SD. Cephalalgiaphobia: a possible specific phobia of illness. J Headache Pain 2007; 8 (01) 56-59
- 20 Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin 2019; 37 (04) 631-649
- 21 Duan J, Yang R, Lu W, Zhao L, Hu S, Hu C. Comorbid Bipolar Disorder and Migraine: From Mechanisms to Treatment. Front Psychiatry 2021; 11: 560138
- 22 Rosado MSV, Silva-Néto R. Headache triggered by sleep deprivation: an observational study. Headache Med 2020; 11 (02) 44-47
- 23 Gelfand AA, Goadsby PJ. The Role of Melatonin in the Treatment of Primary Headache Disorders. Headache 2016; 56 (08) 1257-1266
- 24 Silva-Néto RP, Santos PEMS, Peres MFP. Hypnic headache: A review of 348 cases published from 1988 to 2018. J Neurol Sci 2019; 401: 103-109
- 25 Gelfand AA. Melatonin in the Treatment of Primary Headache Disorders. Headache 2017; 57 (06) 848-849
- 26 Gasparini CF, Smith RA, Griffiths LR. Genetic and biochemical changes of the serotonergic system in migraine pathobiology. J Headache Pain 2017; 18 (01) 20
- 27 Pakalnis A, Splaingard M, Splaingard D, Kring D, Colvin A. Serotonin effects on sleep and emotional disorders in adolescent migraine. Headache 2009; 49 (10) 1486-1492
- 28 May A, Burstein R. Hypothalamic regulation of headache and migraine. Cephalalgia 2019; 39 (13) 1710-1719
- 29 Hjorth O, Frick A, Gingnell M, Engman J, Björkstrand J, Faria V. et al. Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy. Transl Psychiatry 2022; 12 (01) 436
- 30 Noseda R, Kainz V, Borsook D, Burstein R. Neurochemical pathways that converge on thalamic trigeminovascular neurons: potential substrate for modulation of migraine by sleep, food intake, stress and anxiety. PLoS One 2014; 9 (08) e103929
- 31 Hoffmann J, Charles A. Glutamate and Its Receptors as Therapeutic Targets for Migraine. Neurotherapeutics. 2018; 15 (02) 361-370
- 32 Tepper SJ. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache 2018; 58 (Suppl. 03) 238-275
- 33 Arkless K, Argunhan F, Brain SD. CGRP discovery and timeline. In: Handbook of Experimental Pharmacology. Handb Exp Pharmacol 2019; 255: 1-12
- 34 Pellitteri G, Pez S, Nilo A, Surcinelli A, Gigli GL, Lettieri C, Valente M. Erenumab Impact on Sleep Assessed With Questionnaires and Home-Polysomnography in Patients With Migraine: The ERESON Study. Front Neurol 2022; 13: 869677
- 35 De Luca C, Baldacci F, Mazzucchi S, Lombardo I, Curto L, Ulivi M. et al. CGRP inhibitors and oxidative stress biomarkers in resistant migraine: A real-life study with erenumab, fremanezumab and galcanezumab. J Clin Med 2021; 10 (19) 4586
- 36 Peres MFP. One more bite in the understanding of migraine psychiatric comorbidity: the role of eating attitudes. Arq Neuropsiquiatr 2020; 78 (09) 533-534
- 37 Kowacs PA, Sampaio Rocha-Filho PA, Peres MFP, Edvinsson L. The history and rationale of the development of new drugs for migraine treatment. Arq Neuropsiquiatr 2023; 81 (12) 1084-1097
- 38 Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287 (05) 622-627 [Internet]
- 39 Schedlowski M, Enck P, Rief W, Bingel U. Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice. Pharmacol Rev 2015; 67 (03) 697-730
- 40 Gonçalves AL, Ferreira AM, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MFP. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 2016; 87 (10) 1127-1132